Article
Hematology
Masatomo Kuno, Satoshi Yamasaki, Nobuharu Fujii, Yasushi Ishida, Takahiro Fukuda, Keisuke Kataoka, Naoyuki Uchida, Yuta Katayama, Maho Sato, Daishi Onai, Toshihiro Miyamoto, Shuichi Ota, Satoshi Yoshioka, Takahide Ara, Akira Hangaishi, Yoshiko Hashii, Makoto Onizuka, Tatsuo Ichinohe, Yoshiko Atsuta, Yoshihiro Inamoto
Summary: The study compared myeloid neoplasms (MNs) following allogeneic hematopoietic cell transplantation (HCT) versus autologous HCT using a Japanese HCT registry database. The cumulative incidence of MNs was lower after allogeneic HCT than after autologous HCT, and those following allogeneic HCT developed in younger patients and sooner after HCT. Further research is needed to understand the mechanisms of MN development following allogeneic HCT.
AMERICAN JOURNAL OF HEMATOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Riccardo Masetti, Daniele Zama, Davide Leardini, Edoardo Muratore, Silvia Turroni, Patrizia Brigidi, Andrea Pession
Summary: The gut microbiome plays a significant role in hematopoietic stem cell transplantation, with its metabolites mediating interactions between intestinal microbial communities and the host. New data offer a fresh perspective on the role of microbiome-derived metabolites in transplant settings.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Oncology
Li Xuan, Qifa Liu
Summary: Relapse is still the main reason for treatment failure in AML patients undergoing allo-HSCT. Evidence suggests that maintenance therapy post-transplantation, particularly targeted drugs like hypomethylating agents, FLT3 inhibitors, and isocitrate dehydrogenase inhibitors, could benefit AML patients, especially those at high risk.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2021)
Review
Immunology
Adele Dhuyser, Alice Aarnink, Michael Peres, Jyothi Jayaraman, Neda Nemat-Gorgani, Marie Therese Rubio, John Trowsdale, James Traherne
Summary: Allogeneic hematopoietic stem cell transplantation is a life-saving therapy for hematological malignancies. The selection of a suitable donor has traditionally required a fully matched HLA. However, new immunosuppressive strategies have made it possible to recruit viable alternative donors, including haploidentical donors. The importance of KIR-driven NK cell alloreactivity in aHSCT outcomes remains unclear, and the literature shows discrepancies in the evaluation of its clinical benefit.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Ryo Hanaki, Hidemi Toyoda, Shotaro Iwamoto, Mari Morimoto, Daisuke Nakato, Takahiro Ito, Kaori Niwa, Keishiro Amano, Ryotaro Hashizume, Isao Tawara, Masahiro Hirayama
Summary: The study demonstrated that donor-derived M2 macrophages can attenuate the occurrence and severity of GVHD, prolong survival time, and significantly suppress the proliferation of donor T cells through cell-to-cell contact.
IMMUNITY INFLAMMATION AND DISEASE
(2021)
Article
Immunology
Dina Leth Moller, Katrine Kielsen, Claus Henrik Nielsen, Henrik Sengelov, Anders Elm Pedersen, Lars Peter Ryder, Klaus Muller
Summary: This study suggests a role of TSLP in immune reconstitution and alloreactivity post-HSCT.
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY
(2022)
Article
Hematology
Sanam Shahid, Nicholas Ceglia, Jean-Benoit Le Luduec, Andrew Mcpherson, Barbara Spitzer, Theodota Kontopoulos, Viktoria Bojilova, M. Kazim Panjwani, Mikhail Roshal, Sohrab P. Shah, Omar Abdel-Wahab, Benjamin Greenbaum, Katharine C. Hsu
Summary: This study investigated the effects of allo-HCT on AML cells using a novel single-cell proteogenomic approach. The results demonstrated immune-related transcriptional signatures in posttransplant relapses, revealing dysfunction in activated natural killer cells and CD8+ T-cell subsets, as well as an expansion of dysfunctional T cells.
Article
Immunology
Thomas Krueger, Rebekka Wehner, Maik Herbig, Martin Kraeter, Michael Kramer, Jan Moritz Middeke, Friedrich Stoelzel, Catrin List, Katharina Egger-Heidrich, Raphael Teipel, Uta Oelschlaegel, Martin Wermke, Helena Jambor, Manja Wobus, Johannes Schetelig, Korinna Joehrens, Torsten Tonn, Julien Subburayalu, Marc Schmitz, Martin Bornhauser, Malte von Bonin
Summary: Functional impairment of the bone marrow niche, particularly a decrease in mesenchymal stromal cells (MSCs), is associated with cytopenia and graft failure after hematopoietic cell transplantation. Acute graft-versus-host disease (aGvHD) is shown to significantly reduce MSC numbers, and this reduction can be observed before clinical onset of aGvHD. The different phenotypic and functional characteristics of MSCs depending on the occurrence of aGvHD suggest that they may contribute to alloreactivity after transplantation.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Hideaki Fujiwara
Summary: This article discusses the impact of allo-HSCT on intestinal microbiota and metabolites, as well as the mechanisms for regulating experimental GVHD through dietary intervention or metabolites produced by intestinal bacteria post-allo-HSCT. It also summarizes the major findings of microbiome-based immunotherapeutic approaches for tissue protection against experimental GVHD. Understanding the complex relationships within the gut microbiota-metabolites-host tissues axis is crucial for insight into GVHD pathogenesis and the development of new therapeutic strategies.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Oncology
Enrico Maffini, Margherita Ursi, Francesco Barbato, Michele Dicataldo, Marcello Roberto, Elena Campanini, Elisa Dan, Francesco De Felice, Serena De Matteis, Gianluca Storci, Massimiliano Bonafe, Mario Arpinati, Francesca Bonifazi
Summary: Disease relapse post hematopoietic cell transplantation remains a major challenge, with novel cellular and biological therapies showing promise in treating acute leukemia relapse. Understanding the pathobiology of leukemia relapse is crucial for developing new therapeutic strategies, including targeted therapies and novel drug combinations.
FRONTIERS IN ONCOLOGY
(2022)
Article
Medicine, Research & Experimental
Prashanth K. Kandalla, Julien Subburayalu, Clement Cocita, Berengere de Laval, Elena Tomasello, Johanna Iacono, Jessica Nitsche, Maria M. Canali, Wilfried Cathou, Gilles Bessou, Noushin Mossadegh-Keller, Caroline Huber, Guy Mouchiroud, Roland P. Bourette, Marie-France Grasset, Martin Bornhaeuser, Sandrine Sarrazin, Marc Dalod, Michael H. Sieweke
Summary: Therapies involving M-CSF can help boost antiviral immune response in immunosuppressed individuals, particularly those who have undergone hematopoietic cell transplantation. M-CSF promotes myelopoiesis and NK cell differentiation, leading to increased NK cell numbers and antiviral activity.
EMBO MOLECULAR MEDICINE
(2023)
Article
Immunology
Yingying Huo, Linjie Wu, Aiming Pang, Qing Li, Fang Hong, Caiying Zhu, Zining Yang, Weiqian Dai, Yawei Zheng, Qianqian Meng, Jiali Sun, Shihui Ma, Linping Hu, Ping Zhu, Fang Dong, Xin Gao, Erlie Jiang, Sha Hao, Tao Cheng
Summary: Hematopoietic stem cell transplantation is an effective regenerative therapy for various diseases, but our understanding of the reconstitution process is limited. This study reveals the dynamics of transplanted hematopoietic stem and progenitor cells (HSPCs) in humans. Transcriptomic analysis shows that immunoregulatory neutrophil progenitors expressing high levels of the S100A gene family are enriched in peripheral blood stem cells. Patients with acute graft-versus-host disease (aGVHD) have fewer S100Ahigh immunoregulatory neutrophil progenitors, suggesting a potential criterion for identifying high-risk patients.
SCIENCE IMMUNOLOGY
(2023)
Article
Immunology
Lin Li, Jin Yin, Yun Li, Chunyan Wang, Xia Mao, Jia Wei, Yang Cao, Na Wang, Li Lin, Jinhuan Xu, Yicheng Zhang
Summary: This study compared pegylated granulocyte colony-stimulating factor (peg-G-CSF) with non-peg-G-CSF for hematopoietic stem cell mobilization in allogeneic hematopoietic stem cell transplantation. The mobilization with peg-G-CSF resulted in higher numbers of specific cells and a reduced incidence of severe acute graft-versus-host disease after transplantation.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Immunology
Shan Jiang, Han Yan, Xuan Lu, Ruowen Wei, Haoran Chen, Ao Zhang, Wei Shi, Linghui Xia
Summary: In recent years, haploidentical transplantation technology has advanced, leading to increased availability of donors and improved conditions for elderly AML patients to receive allogeneic hematopoietic stem cell transplantation. This article summarizes the pre-transplant assessment methods, various sources of donors, conditioning regimens, and post-transplant complication management based on large-scale clinical studies.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Friedrich Wittenbecher, Stella Lesch, Stefan Kolling, Igor-Wolfgang Blau, Lam Vuong, Franziska Borchert, Kamran Movasshagi, Carola Tietze-Buerger, Olaf Penack, Johann Ahn, Lars Bullinger, Marco Frentsch, Il-Kang Na
Summary: In this study, a comprehensive phenotypic analysis of 26 immune cell subsets was conducted using multicolor flow cytometry. The analysis was performed on only 100 μL of whole blood samples and provided extensive longitudinal data. The study found that the relative quantitative immune cell subset composition in recipients approached that of healthy donors after 180 days post alloHSCT. The proposed method could be a time efficient approach for broad immune assessment in future clinical studies.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Pharmacology & Pharmacy
Sana Arnouk, Timo W. M. De Groof, Jo A. Van Ginderachter
Summary: The presence and activity of tumor-infiltrating immune cells, such as activated CD8+ T cells and macrophages, play a crucial role in tumor progression and therapy response. Understanding the immune infiltrate in tumors is important for predicting prognosis, optimizing therapeutic success, and monitoring treatment outcomes.
ADVANCED DRUG DELIVERY REVIEWS
(2022)
Article
Biochemical Research Methods
Isabelle Scheyltjens, Hannah Van Hove, Karen De Vlaminck, Daliya Kancheva, Jonathan Bastos, Monica Vara-Perez, Ana Rita Pombo Antunes, Liesbet Martens, Charlotte L. Scott, Jo A. Van Ginderachter, Yvan Saeys, Martin Guilliams, Niels Vandamme, Kiavash Movahedi
Summary: This protocol provides a detailed workflow for single-cell multi-omic analysis of the mouse brain immune compartment. It includes steps for brain dissection, cell dissociation, high-dimensional flow cytometry, droplet-based single-cell RNA sequencing, and analysis of the data. This optimized workflow allows for a comprehensive assessment of immune cell heterogeneity and activation in the brain, which is crucial for studying neurological disorders.
Article
Hematology
Marta Sobas, Jean-Jacques Kiladjian, Yan Beauverd, Natalia Curto-Garcia, Parvis Sadjadian, Lee Yung Shih, Timothy Devos, Dorota Krochmalczyk, Serena Galli, Maria Bieniaszewska, Ilona Seferynska, Mary Frances McMullin, Anna Armatys, Adrianna Spalek, Joanna Waclaw, Mihnea Zdrenghea, Laurence Legros, Francois Girodon, Krzysztof Lewandowski, Anna Angona Figueras, Jan Samuelsson, Aitor Abuin Blanco, Pascale Cony-Makhoul, Angela Collins, Chloe James, Rajko Kusec, Marie Lauermannova, Maria Sol Noya, Malgorzata Skowronek, Lukasz Szukalski, Anna Szmigielska-Kaplon, Marielle Wondergem, Iryna Dudchenko, Joanna Gora Tybor, Kamel Laribi, Anna Kulikowska de Nalecz, Jean-Loup Demory, Katell Le Du, Sonja Zweegman, Carlos Besses Raebel, Radek Skoda, Stephane Giraudier, Martin Griesshammer, Claire N. Harrison, Jean-Christophe Ianotto
Summary: In this study of young MPN patients, high rates of thrombotic events and disease transformation were observed. JAK2V617F mutation and hyperviscosity symptoms were identified as risk factors, with splenomegaly potentially being a new risk factor for transformation in essential thrombocythemia. Conventional risk scores were not able to predict survival for young ET or polycythemia vera patients.
Article
Medicine, Research & Experimental
Marco Erreni, Francesca D'Autilia, Roberta Avigni, Evangelia Bolli, Sana M. Arnouk, Kiavash Movahedi, Pieterjan Debie, Achille Anselmo, Raffaella Parente, Cecile Vincke, Fijs W. B. van Leeuwen, Paola Allavena, Cecilia Garlanda, Alberto Mantovani, Andrea Doni, Sophie Hernot, Jo A. Van Ginderachter
Summary: Nanobodies (Nbs) have been identified as an elegant alternative to conventional monoclonal antibodies for cancer therapy, but there is a lack of detailed microscopic insight into the in vivo pharmacokinetics of different Nb formats in tumor-bearers, especially for the targeting of pro-tumoral tumor-associated macrophages (TAMs) located in less penetrable tumor regions.
Review
Oncology
Romina Mora Barthelmess, Benoit Stijlemans, Jo A. Van Ginderachter
Summary: The aim of this review is to summarize the available information regarding the MIF family in cancer. MIF and DDT are both highly expressed in cancer patients and their functions are related to 9 out of 10 hallmarks of cancer, indicating their potential as therapeutic targets. New diagnostic methods and treatments have decreased the mortality rates of cancer patients, but further improvements are warranted based on the identification of novel tumor-promoting molecules.
Article
Hematology
Hubert Schrezenmeier, Austin Kulasekararaj, Lindsay Mitchell, Regis Peffault de Latour, Timothy Devos, Shinichiro Okamoto, Richard Wells, Evan Popoff, Antoinette Cheung, Alice Wang, Ioannis Tomazos, Yogesh Patel, Jong Wook Lee
Summary: This study identifies LDH levels as an important determinant of fatigue and quality of life outcomes in patients with PNH.
ANNALS OF HEMATOLOGY
(2023)
Article
Hematology
Britta Hoechsmann, Regis Peffault de Latour, Anita Hill, Alexander Roeth, Timothy Devos, Christopher J. Patriquin, Wen-Chien Chou, Deepak Jain, Ke Zu, Chuntao Wu, Jong Wook Lee
Summary: The objective of this analysis was to identify risk factors for thromboembolic events (TE) in patients with paroxysmal nocturnal hemoglobinuria (PNH) who were not treated with C5 inhibitors. Multivariable analysis revealed that a history of TE, >= 30% GPI-negative granulocytes, and LDH ratio >= 1.5 x ULN with >= 2 high disease activity criteria are risk factors for TE in PNH patients.
ANNALS OF HEMATOLOGY
(2023)
Article
Hematology
Alexandre Theocharides, Heinz Gisslinger, Valerio De Stefano, Vincenzo Accurso, Alessandra Iurlo, Timothy Devos, Miklos Egyed, Eric Lippert, Regina Garcia Delgado, Nathan Cantoni, Anders E. A. Dahm, Damianos Sotiropoulos, Erik Houtsma, Aoife Smyth, Amir Iqbal, Paola Di Matteo, Mike Zuurman, Peter A. W. te Boekhorst
Summary: This study demonstrates that ruxolitinib treatment in patients with polycythemia vera who are resistant and/or intolerant to hydroxyurea maintains durable hematocrit control, reduces the need for phlebotomies, and is generally well tolerated.
EUROPEAN JOURNAL OF HAEMATOLOGY
(2023)
Review
Immunology
Neema Ahishakiye Jumapili, Maida Zivalj, Romina Mora Barthelmess, Geert Raes, Timo W. M. De Groof, Nick Devoogdt, Benoit Stijlemans, Cecile Vincke, Jo A. Van Ginderachter
Summary: mAbs have limitations in their distribution and penetration in tumor microenvironment, as well as their ability to reach the brain. Nanobodies, being smaller in size, possess superior abilities in tumor penetration and infiltration into brain tumors. However, the rapid clearance of nanobodies from circulation may affect their suitability for therapy, although their noncovalent binding to albumin can help increase their serum half-life.
EUROPEAN JOURNAL OF IMMUNOLOGY
(2023)
Review
Pharmacology & Pharmacy
Tessa De Pauw, Lynn De Mey, Jens M. Debacker, Geert Raes, Jo A. Van Ginderachter, Timo W. M. De Groof, Nick Devoogdt
Summary: Monoclonal antibodies have played a significant role in personalized medicine for cancer, but their size and complexity may hinder certain cancer diagnosis and therapy applications. Nanobodies, with their unique structure and pharmacological features, have shown promising potential as complementary tools for cancer diagnostics and therapeutics. This overview provides insights into nanobody-based diagnostics and therapeutics that have been tested in clinical trials and highlights upcoming preclinical developments.
EXPERT OPINION ON INVESTIGATIONAL DRUGS
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Odrade Gondry, Catarina Xavier, Laurens Raes, Johannes Heemskerk, Nick Devoogdt, Hendrik Everaert, Karine Breckpot, Quentin Lecocq, Lore Decoster, Christel Fontaine, Denis Schallier, Sandrine Aspeslagh, Ilse Vaneycken, Geert Raes, Jo A. Van Ginderachter, Tony Lahoutte, Vicky Caveliers, Marleen Keyaerts
Summary: Macrophages play a vital role in the body, and anti-inflammatory macrophages targeting CD206 are involved in various diseases. This study evaluated the safety and biodistribution of a PET tracer targeting CD206 in human subjects, and found that the tracer was safe, rapidly cleared from the blood, and enabled high contrast imaging at 90 minutes after injection. Preliminary results showed higher tumor uptake in patients with disease progression.
JOURNAL OF NUCLEAR MEDICINE
(2023)
Article
Immunology
Emile J. Clappaert, Daliya Kancheva, Jan Brughmans, Ayla Debraekeleer, Pauline M. R. Bardet, Yvon Elkrim, Dagmar Lacroix, Maida Zivalj, Ahmed E. I. Hamouda, Jo A. Van Ginderachter, Sofie Deschoemaeker, Damya Laoui
Summary: This study found that while Flt3L treatment can increase all cDC subsets in the tumor, it does not reduce tumor growth in any of the models. In addition, in some cases, Flt3L treatment also leads to an increase in CD81(+)migcDC1 subset, which has Treg-inducing potential. Overall, increasing cDC numbers in the tumor alone may not improve anti-tumor responses and may not be beneficial for cancer treatment.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Oncology
Maida Zivalj, Jo A. Van Ginderachter, Benoit Stijlemans
Summary: The aim of this review is to summarize the available information regarding Lipocalin-2 in tumor progression. Lipocalin-2 expression is correlated with tumorigenesis and can be considered as a biomarker and potential drug target in cancer therapy.
Article
Pharmacology & Pharmacy
Maximilian Scherger, Yannick A. A. Pilger, Judith Stickdorn, Patric Komforth, Sascha Schmitt, Sana M. M. Arnouk, Els Lebegge, Kaloian Koynov, Hans-Joachim Rader, Jo A. A. Van Ginderachter, Lutz Nuhn
Summary: In this study, a procedure is demonstrated for site-specific reversible bioconjugation of genetically engineered single domain antibodies, called nanobodies, using self-immolative linkers (SILs). The flow cytometry and microscopy images confirm cellular uptake and biological affinity of the modified nanobodies. This strategy can be extended to other therapeutically relevant representatives of nanobodies, highlighting the versatility of this reversible reductive-responsive bioconjugation in a broad field of applications.
ADVANCED THERAPEUTICS
(2023)
Article
Hematology
Timothy Devos, Dominik Selleslag, Nikki Granacher, Violaine Havelange, Fleur Samantha Benghiat
Summary: This article provides recommendations for the use of ruxolitinib in Belgian myelofibrosis patients, including dose optimization/monitoring, adverse events, and interruption/rechallenge management.